Anti-Abortion Group Holds Up FDA Nominee
Susan B. Anthony List is blocking Heidi Overton's confirmation until the administration restores an in-person dispensing requirement for mifepristone.
Updated on Nov. 11, 2026 in Legislative Policy
Live Poll
Should abortion pills like mifepristone be available by mail without an in-person visit?
President Donald Trump nominated Heidi Overton to be commissioner of the Food and Drug Administration. Susan B. Anthony List said Wednesday it will hold up the nomination, arguing it is not satisfied Overton will restrict abortion medication.
Why it matters
The dispute centers on mifepristone, whose mail-order regime from the Biden era remains in effect. The hold shows how advocacy pressure on abortion drug rules can directly shape the confirmation of a top federal health regulator.
Susan B. Anthony List cites an estimate of 15,000 unborn babies a month in pro-life states, a figure the group attributes to its own claim. Whether the administration will restore the in-person dispensing requirement for mifepristone has not been announced.
The players
Heidi Overton
Overton is the nominee for FDA commissioner, a post overseeing the agency that regulates drugs including mifepristone.
Susan B. Anthony List
Susan B. Anthony List is a national anti-abortion advocacy organization that lobbies for restrictions on abortion and abortion medication.
The details
In a written statement issued Wednesday morning, Susan B. Anthony List said it would hold up Overton's nomination until its demands are met. The group said it is seeking restoration of the in-person dispensing requirement for mifepristone, and noted that a Trump-appointed federal judge in Texas briefly ordered the FDA to decertify the drug before the Supreme Court reversed that order.
Timeline
November 11, 2026: Susan B. Anthony List issued its written statement holding up the nomination.
Legislative Policy Context
The fight revisits the FDA's mifepristone REMS, whose in-person dispensing requirement was dropped during the Biden administration to allow mail-order access. Advocacy groups are now using the confirmation process to press for that requirement's return.
The outcome could determine whether mifepristone stays available by mail or requires an in-person pickup at a clinic or pharmacy. Patients and providers would feel any change in how the drug is dispensed.
The takeaway
Confirmation fights are becoming a lever for advocacy groups seeking changes to drug access rules. Readers should watch whether the FDA leadership vote proceeds and whether the dispensing requirement is revisited.
Further reading
For related coverage, see Legislative Policy on the health and regulatory fights in Congress.
Source note: This article includes information reported by Raw Story.
Live Poll
Should abortion pills like mifepristone be available by mail without an in-person visit?
